Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and ACADIA Pharmaceuticals Inc.

SG&A Expenses Surge in Biopharma Giants Over a Decade

__timestampACADIA Pharmaceuticals Inc.Intra-Cellular Therapies, Inc.
Wednesday, January 1, 20143274800010337679
Thursday, January 1, 20159080400018187286
Friday, January 1, 201618645600024758063
Sunday, January 1, 201725506200023666957
Monday, January 1, 201826575800030099855
Tuesday, January 1, 201932563800064947625
Wednesday, January 1, 2020388661000186363444
Friday, January 1, 2021396028000272611040
Saturday, January 1, 2022369090000358782000
Sunday, January 1, 2023402466000409864000
Loading chart...

Unleashing insights

A Decade of SG&A Evolution in Biopharma

In the dynamic world of biopharmaceuticals, operational costs are pivotal in shaping a company's financial health. Over the past decade, Intra-Cellular Therapies, Inc. and ACADIA Pharmaceuticals Inc. have demonstrated intriguing trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ACADIA Pharmaceuticals saw a staggering 1,130% increase in SG&A expenses, peaking in 2023. Meanwhile, Intra-Cellular Therapies experienced an even more dramatic rise, with expenses surging by over 3,860% during the same period. This growth reflects strategic investments in marketing and administration, crucial for their competitive edge. Notably, both companies showed a significant uptick in expenses post-2019, aligning with industry-wide trends of increased spending on innovation and market expansion. As these companies continue to evolve, understanding their financial strategies offers valuable insights into the broader biopharma landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025